ABSTRACT
study, changes in certain virologic markers have been analyzed in peripheral blood and lymphoid tissue during antiretroviral therapy. Sixteen HIV-infected individuals who were receiving antiretroviral therapy with zidovudine for 26 months were randomly assigned either to continue on zidovudine alone or to add didanosine for 8 weeks. Lymph node biopsies were performed at baseline and after 8 weeks. Viral burden (i.e., HIV DNA copies per 106 mononuclear cells) and virus replication in mononuclear cells isolated from peripheral blood and lymph node and plasma viremia were determined by semiquantitative polymerase chain reaction assays. Virologic and immunologic markers remained unchanged in peripheral blood and lymph node of patients who continued on zidovudine alone. In contrast, a decrease in virus replication in lymph nodes was observed in four of six patients who added didanosine to their regimen, and this was associated with a decrease in plasma viremia. These results indicate that decreases in plasma viremia detected during antiretroviral therapy reflect downregulation of virus replication in lymphoid tissue.
Several immunologic and virologic markers including CD4+
lymphocyte counts, serum f32-microglobulin and neopterin, p24 antigenemia, plasma viremia measured by culture or by nucleic acid detection, and quantitation of human immunodeficiency virus (HIV) DNA (viral burden) and HIV RNA in mononuclear cells isolated from peripheral blood are currently used in monitoring the effect of antiretroviral therapy in HIV-infected subjects. A common finding following initiation of antiretroviral therapy with nucleoside reverse transcriptase (RT) inhibitors is a transient improvement in these parameters that is maximal between weeks 4 and 16 of therapy and that is generally more pronounced in patients in advanced stages of disease who are receiving combination therapy (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) . Most of these markers seem to be valid in predicting progression of HIV disease (11) (12) (13) ; however, their usefulness in assessing the response to antiretroviral therapy is still debated. With regard to the CD4+ lymphocyte count and the serum p24 antigen
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level, which are the most widely used surrogate markers in clinical practice, the discrepancy between the transient improvement of these parameters observed following antiretroviral therapy and the absence of demonstrable clinical benefit in early stage disease has further called into question the validity of these markers in the evaluation of response to therapy (refs. 14-16 and 1). Furthermore, a major caveat with regard to the interpretation of changes in surrogate markers in peripheral blood following antiretroviral therapy is the possibility that they may not necessarily reflect the situation in other anatomic sites such as lymphoid organs that are a major reservoir of HIV and primary sites for HIV replication (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) Treatment Regimens. Patients were randomly assigned either to remain on zidovudine (group 1) or to add didanosine (200 mg) twice daily to their zidovudine regimen (group 2) until completion of the week 8 lymph node biopsy. Due to a clerical error, two patients who were randomized to add didanosine to their zidovudine regimens never received didanosine from their clinical site and are included in group 1 for analysis. An intention-to-treat analysis was also done and is not significantly different from the as-treated analysis presented (data not shown).
Characteristics of the Study Population. The clinical characteristics of the study participants at entry are listed in Table  1 . The mean baseline CD4+ lymphocyte count for the entire group was 406 cells per ,ul. There were no significant differences in any of the baseline variables between those randomized to continue on zidovudine alone (group 1) versus those who added didanosine to their regimen (group 2).
Evaluation ofPatients. Lymphocyte phenotypic analysis was performed by flow cytometry on day 0 (day of the baseline lymph node biopsy) and at weeks 4 and 8. Quantitation of HIV-1 DNA and RNA in mononuclear cells from peripheral blood and lymph node as well as HIV-1 plasma viremia were determined by semiquantitative PCR on day 0 and week 8. These virologic assays were performed by investigators who were blinded with regard to treatment group assignments.
Lymph Node Biopsies. The mean size of the excised lymph nodes was 1.6 x 0.6 cm. Eighty-eight percent of the excised lymph nodes were axillary and 12% were cervical. The only complication related to the lymph node biopsies was a probable wound infection requiring incision and drainage in one patient after the week 8 biopsy (complication rate, 3.1%).
Determination of p24 Antigenemia. Immune complexdissociated (ICD) p24 antigen levels were determined from serum by a commercially available ELISA method (Coulter).
Analysis of HIV-1 DNA in Peripheral Blood and Lymph Node Mononuclear Cells by PCR. Mononuclear cells were obtained from peripheral blood and lymph node as described and pelleted cells were frozen at -70°C until use (23) . Lysates corresponding to 105 cells in 50 ,la were amplified for 30 cycles using a primer pair (SK 145/101) specific for the HIV-1 gag gene. Serial dilutions (1:10) of 8E5 cells, a chronically HIVinfected T-cell line containing one proviral copy per cell, were used as positive controls. Negative controls included lysis buffer and Jurkat cell lysates. Amplified products were hybridized to y-32P-labeled gag-specific probe (SK102) and sep- (29) . Positive controls were serial dilutions of a plasmid cDNA construct containing HIV-1 exons 1 and 4E (30) . Negative controls included herring sperm DNA (used as the diluent for the plasmid cDNA) and cDNA obtained from Jurkat cells and normal volunteer peripheral blood mononuclear cell RNA. Amplified products were separated on 6% polyacrylamide gels by electrophoresis. Standard autoradiography and PhosphorImager analysis were used for visualization.
To normalize for RNA input, 1/25th of each reverse transcription was amplified with a primer pair (sense primer,5 '-gaa ccc tga ccc tgc cgt gta cc-3'; antisense primer, 5'-agc cgc agc gtc atg agc aga tta aac ccg-3') specific for human T-cell receptor Co mRNA.
All four samples from each patient (peripheral blood and lymph node from weeks 0 and 8) were amplified simultaneously in order to avoid PCR run-to-run variability. Quantitation of HIV-1 RNA was accomplished by normalization of the HIV-1 amplification signal to the Ca signal and interpolation into the control cDNA serial dilution curve. Samples were run in at least two separate experiments and the means are reported as fg of HIV-1 RNA per 1.5 ,ug of total RNA. Determination of Plasma Viremia by RT-PCR. Quantitation of HIV-1 RNA copy number in plasma was determined as described (5) . Briefly, duplicate 1-ml aliquots of plasma were centrifuged at 23,000 x g at 4°C for 1 hr to pellet virions after which the pellet was treated with guanidinium thiocyanate and RNA was extracted with phenol/chloroform. Reverse transcription utilized Moloney murine leukemia virus RT (Bethesda Research Laboratories). cDNA was amplified for 30 cycles with unmodified SK38 and biotinylated SK39 (gag specific) primers. Amplified products were captured on avidincoated microtiter plates and hybridized to horseradish peroxidase-labeled SK19 internal probe. Substrate solution was added and the optical density of each well was measured at 490 nm. Copy number per ml of plasma was determined by interpolation into a serial dilution curve of known copy numbers using a gag gene cDNA construct. (Fig. 1A) . In those who added didanosine to their ongoing zidovudine therapy (group 2), the mean CD4+ lymphocyte count was 394 ± 74 cells per ,lI at baseline and 436 ± 114 cells per ,ul at week 8 (P = 0.44). One patient in group 2 (Fig. 1B, o) Fig. 2A) . Although the magnitude of this increase was <20% above baseline, it was statistically significant (P = 0.05) because 9 of the 10 patients in this group showed increases in viral burden in peripheral blood mononuclear cells. A slight increase in viral burden was observed in lymph node mononuclear cells (mean HIV DNA copies per 106 cells, 4233 ± 4391 at baseline and 4876 ± 3698 at week 8; Fig. 2A ), but this was not significant (P = 0.33). In patients who added didanosine to zidovudine (group 2), the decreases in viral burden observed in both peripheral blood mononuclear cells (from 3A). In contrast, a sharp decrease (20.5 order of magnitude) in the levels of HIV RNA in lymph node mononuclear cells was observed in four of six patients in group 2 ( Fig. 3B; Fig.   4 , patients 1,3,5, and 6). Patients in group 2 overall had a mean decrease of 338 fg in lymph node HIV RNA, which did not reach statistical significance compared with a mean decrease of 30 fg in group 1 (P = 0.1). However, four of six patients had substantial decreases in lymph node HIV RNA (mean decrease, 621 fg). HIV-1 RNA levels in lymph node mononuclear cells remained unchanged in patient 2, whereas they increased by 1.3 order of magnitude in patient 4 (Fig. 4) .
Determination of Plasma Viremia by RT-PCR. Plasma viremia remained unchanged in patients who remained on zidovudine alone (group 1): the mean HIV-1 RNA copy number per ml of plasma was 40,128 ± 68,100 at baseline and 86,360 ± 163,451 at week 8 (P = 0.45; Fig. 3A) . In contrast, plasma viremia decreased by >0.5 order of magnitude in four of six patients (patients 1, 3, 5, and 6) who added didanosine to their ongoing zidovudine therapy (Figs. 3B and 4) . Plasma viremia decreased by 0.4 order of magnitude in patient 2 and remained unchanged in patient 4 (Fig. 4) . The mean HIV-1 RNA copy number per ml of plasma in group 2 was 179,927 + 85,761 at baseline and 46,730 ± 49,386 at week 8 (P = 0.02; Fig. 3B ).
Correlation of Changes in Viral Replication in Lymph Node Mononuclear Cells and Plasma Viremia. In all of the patients who had decreases in plasma viremia of >0.5 order of magnitude, there was also a decrease in the levels of HIV-1 replication in lymph node mononuclear cells (Fig. 4, patients  1, 3 , 5, and 6). Patient 2 had a moderate decrease (0.4 order of magnitude) in plasma viremia but no significant change in the levels of virus replication in lymph node (Fig. 4) . Plasma viremia did not change in patient 4, and this patient had a sharp increase in the levels of virus replication in lymph node (Fig.  4) . Only two of the five patients with reductions in plasma (23, (25) (26) (27) 31) . This latter observation may represent a major limitation for the use of surrogate markers from peripheral blood in order to evaluate the response to antiretroviral therapy. In this regard, in the present study we have confirmed that the levels of viral burden (i.e., HIV DNA copies per 106 mononuclear cells) and virus replication were greater in lymph nodes compared to peripheral blood by factors of 3 and >200, respectively (23, 25, 26) . It is therefore important to determine whether changes in virologic measures in peripheral blood correlate with those detected in lymphoid tissue during antiretroviral therapy.
In this study, virologic measures including ICD p24 antigenemia, plasma viremia, viral burden, and replication in mononuclear cells isolated from peripheral blood and lymph node remained virtually unchanged over an 8-week 
